drugset / Trial / NCT05885503
Efficacy and Safety of RC28-E Versus Aflibercept in Diabetic Macular Edema
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate efficacy and safety of RC28-E compared with Aflibercept in subjects with diabetic macular edema.
Timeline
- Start
- 2023-06-08
- Primary completion
- 2026-06
- Completion
- 2026-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Aflibercept | Protein / enzyme biologic | 2 mg | Intravitreal |
| Subject | RC28-E | Protein / enzyme biologic | 2 mg | Intravitreal |